SCHEMBL10085342

SCHEMBL10085342

COCC(=O)Nc1nc2c(s1)CN(c1cncc(C)c1)CC2

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 12/20 0.63
PIK3CD O00329 1/20 0.48
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
ALOX15 P16050 1/20 0.44
SLC27A1 Q6PCB7 1/20 0.43
NTRK1 P04629 1/20 0.43
PRKDC P78527 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
GCK P35557 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085338 0.90 PIK3CG (0.79) PIK3CGPIK3CDKDM4ESMN1; SMN2MEN1
SCHEMBL10085716 0.87 PIK3CG (0.59) PIK3CGPIK3CDKDM4ESMN1; SMN2MEN1
SCHEMBL10085345 0.86 PIK3CG (0.76) PIK3CGPIK3CDSLC27A1NTRK1PRKDC
SCHEMBL10085340 0.83 PIK3CG (0.78) PIK3CGPIK3CDALDH1A1SLC27A1NTRK1
SCHEMBL10085434 0.81 PIK3CG (0.80) PIK3CGPIK3CDKDM4ESMN1; SMN2MEN1
SCHEMBL10085354 0.80 PIK3CG (0.79) PIK3CGPIK3CDKDM4ESMN1; SMN2MEN1
SCHEMBL10085346 0.79 PIK3CG (0.82) PIK3CGPIK3CDNTRK1PRKDCGCK
SCHEMBL10085356 0.77 PIK3CG (1.00) PIK3CGPIK3CDSMN1; SMN2ALDH1A1MAPT
SCHEMBL17455003 0.76 SMO (0.64)
SCHEMBL609523 0.76 PIK3CG (1.00) PIK3CGPIK3CDNTRK1PRKDCNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524906-B2 Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-20120039849-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120039849-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIK3CG PIK3CG 3/4885PIK3CD 2/4885KDM4E 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.